Short-term and long-term sequelae in intrauterine growth retardation (IUGR)

Stefania Longo1, Lina Bollani, Lidia Decembrino

  • 1Neonatal Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. sty.longo@gmail.com

Insights

Intrauterine Growth Retardation (IUGR) impacts fetal growth, leading to increased risks of neonatal complications and long-term metabolic issues. Identifying risk factors for infants born Small for Gestational Age (SGA) is crucial for improving outcomes.

Area of Science:

  • Perinatal Medicine
  • Neonatology
  • Endocrinology

Background:

  • Intrauterine Growth Retardation (IUGR) signifies fetal growth below normal potential for gestational age.
  • Infants born Small for Gestational Age (SGA) weigh below the 10th percentile, often resulting from IUGR.
  • Suboptimal fetal growth is a significant contributor to perinatal mortality and morbidity.

Purpose of the Study:

  • To highlight the acute neonatal consequences of IUGR.
  • To emphasize the long-term metabolic and endocrinological sequelae associated with IUGR.
  • To underscore the need for prospective studies on SGA risk factors.

Main Methods:

  • Review of existing literature on IUGR and SGA.
  • Analysis of neonatal complications including metabolic, hematological, and thermoregulatory disturbances.
  • Examination of long-term health risks such as metabolic syndrome and endocrinopathies.

Main Results:

  • IUGR leads to acute neonatal issues like metabolic disturbances, RDS, NEC, and ROP.
  • Individuals with IUGR face elevated risks for type 2 diabetes mellitus, obesity, hypertension, dyslipidemia, insulin resistance, and cardiovascular disease.
  • Endocrinological sequelae include short stature, premature adrenarche, and PCOS; neurological deficits are also increased.

Conclusions:

  • IUGR poses significant short-term and long-term health risks for infants.
  • Early growth delay and prematurity are linked to neurological and cognitive impairments.
  • Further research into SGA risk factors is essential for reducing perinatal and long-term adverse outcomes.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...